A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

NCT02039063 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: E6011 2 mg/kg
DRUG: E6011 5 mg/kg
DRUG: E6011 10 mg/kg
DRUG: E6011 15 mg/kg

Sponsor

EA Pharma Co., Ltd.